Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33801
Title: Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis.
Austin Authors: Reynolds, Gemma K;Sim, Beatrice;Spelman, Tim;Thomas, Ashmitha;Longhitano, Anthony;Anderson, Mary Ann;Thursky, Karin;Slavin, Monica;Teh, Benjamin W
Affiliation: Dpartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Infectious Diseases, Austin Health, Melbourne, Victoria.
National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Infectious Diseases
Department of Infectious Diseases, Barwon Health, Melbourne, Victoria.
Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria.
Issue Date: Dec-2023
Date: 2023
Publication information: Critical Reviews in Oncology/Hematology 2023-12; 192
Abstract: A registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran's Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 - 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0.16 - 0.34) were severe. Late infections were as common as early infections (IRR = 0.86, 95% CI: 0.38 - 1.98). All-grade infections, bacterial and viral infections were highest in myeloma patients at 57%, 37% and 28% respectively. Patients with NHL more commonly experienced late infections. Pooled rate of invasive candidiasis/yeast infections was 2% in studies utilizing anti-yeast prophylaxis. This review identified a high rate of all-grade infections, moderate rate of severe infections, and myeloma as a high-risk haematological group.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33801
DOI: 10.1016/j.critrevonc.2023.104134
ORCID: 
Journal: Critical Reviews in Oncology/Hematology
Start page: 104134
PubMed URL: 37739146
ISSN: 1879-0461
Type: Journal Article
Subjects: CAR-T
Cellular therapies
Infections
Lymphoma
Myeloma
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Nov 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.